Altium Capital Management LLC Buys Shares of 264,562 Alphatec Holdings, Inc. (NASDAQ:ATEC)

Altium Capital Management LLC acquired a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 264,562 shares of the medical technology company's stock, valued at approximately $2,429,000. Altium Capital Management LLC owned 0.19% of Alphatec at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of ATEC. R Squared Ltd purchased a new position in Alphatec in the 4th quarter valued at $29,000. Nisa Investment Advisors LLC raised its holdings in Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company's stock worth $43,000 after purchasing an additional 4,234 shares in the last quarter. Newton One Investments LLC acquired a new stake in Alphatec in the fourth quarter valued at about $50,000. XTX Topco Ltd purchased a new position in shares of Alphatec during the 3rd quarter worth approximately $69,000. Finally, AlphaQuest LLC purchased a new position in Alphatec in the fourth quarter worth $80,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Alphatec Trading Up 5.1 %

ATEC stock traded up $0.55 during trading on Wednesday, reaching $11.38. 675,558 shares of the stock traded hands, compared to its average volume of 2,040,237. The business's 50 day moving average price is $10.37 and its 200-day moving average price is $9.56. The firm has a market capitalization of $1.64 billion, a PE ratio of -8.89 and a beta of 1.20. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $13.79.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.04). The business had revenue of $176.79 million for the quarter, compared to analyst estimates of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. As a group, sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Piper Sandler lifted their price target on Alphatec from $12.00 to $13.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. StockNews.com raised shares of Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price target on shares of Alphatec in a report on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Alphatec in a report on Monday, April 14th. Finally, Barclays upped their target price on Alphatec from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Wednesday, January 22nd. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $17.67.

Insider Activity

In related news, EVP David Sponsel sold 33,732 shares of the firm's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $10.83, for a total transaction of $365,317.56. Following the sale, the executive vice president now directly owns 668,977 shares in the company, valued at approximately $7,245,020.91. This trade represents a 4.80 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Patrick Miles sold 12,691 shares of the firm's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $10.64, for a total transaction of $135,032.24. Following the sale, the chief executive officer now directly owns 5,857,603 shares of the company's stock, valued at approximately $62,324,895.92. The trade was a 0.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 272,113 shares of company stock valued at $3,121,225. Company insiders own 22.80% of the company's stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.